RPRX - Company ID 0001802768
The table below shows Royalty Pharma plc's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $630.58M | $609.29M | $578.66M | $568.25M | $564.69M | $537.27M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $39.79M | $50.50M | $300.50M | $50.50M | $500.00K | $500.00K |
Royalty Pharma plc reported annual revenue of $2.38B for fiscal year 2025. That is up 5.1% from $2.26B in fiscal 2024. Over the 8 fiscal years shown, annual revenue grew from $1.79B (FY 2018) to $2.38B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $159.49M |
| $118.73M |
| $179.77M |
| $110.70M |
| $56.72M |
| $54.71M |
| Operating income | $563.04M | $427.16M | $209.80M | $534.18M | $735.07M | $269.63M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $294.69M | $288.22M | $30.18M | $239.35M | $543.99M | $102.00M |
| EPS (diluted) | $0.67 | $0.67 | $0.07 | $0.55 | $1.21 | $0.23 |